<?xml version="1.0" encoding="UTF-8"?>
<p id="Par73">The evolution of influenza vaccine development has shown a trend of cell-based vaccines gradually taking the place of traditional egg-based manufacture. With the plethora of next-generation vaccines currently under development, WHO expects a universal influenza A vaccine to be in advanced clinical trials as early as 2027 [
 <xref ref-type="bibr" rid="CR98">98</xref>]. Although many candidates have shown promising results in preclinical studies, demonstrating clinical safety and efficacy in a human population remains the most significant hurdle towards regulatory approval.
</p>
